复星医药自研创新药抗PD-1单抗汉斯状欧盟获批上市

每日经济新闻
06 Feb

每经AI快讯,2025年2月5日,复星医药(600196.SH;02196.HK)宣布,控股子公司复宏汉霖(02696.HK)自主研发的抗PD-1单抗斯鲁利单抗注射液(欧盟商品名:Hetronifly®,中国境内商品名:汉斯状®)联合卡铂和依托泊苷用于广泛期小细胞肺癌(ES-SCLC)成人患者一线治疗的上市许可申请(MAA)于近日获欧盟委员会(即European Commission)批准。据此,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10